Close
APE 2026

NeuroGeneration Recruits Top Scientist To Direct New Division of Biotherapeutics and Drug Discovery

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Abbott to Acquire Cancer Test Maker...

In a recent move, Abbott has gone ahead and...

New Policy to Boost Medical Device...

Beijing has gone on to release a new policy...

US Lawmakers Push Access For AI-Powered...

The US bipartisan legislation, which was introduced in the...
senior research neuroscientist from The Salk Institute, Mohamedi Kagalwala PhD, has been recruited to head NeuroGeneration's new laboratories in La Jolla, California. Dr. Kagalwala, an expert on neural stem cells, will become director of the new Division of Biotherapeutics and Drug Discovery.
 
"I am extremely pleased to lead NeuroGeneration's new Division and expand its technology of adult neural stem cells for Parkinson's disease. It will allow us to develop personalized iPS cell therapies for degenerative brain disorders," said Dr. Kagalwala. "In addition, by investigating intrinsic neurogenesis and brain repair mechanisms, our team will be able to modify discrete molecular mechanisms during aging and neurodegenerative changes. We will then be in a better position to influence the environment, either with drugs or cellular therapies, to prevent the progression of disease and facilitate brain repair."
 
This new Division will complement the neural stem cell therapy studies for Parkinson's disease and other Atypical Parkinsonism led by Dr. Michel Levesque, NeuroGeneration's scientific founder.
 
Within the new facility providing core state of the art technologies, NeuroGeneration will expand its bioinformatic platforms to include personalized neurogenomic, analysis for drug target discovery for aging, Parkinson's disease, Stroke, Amyotrophic Lateral Sclerosis, Alzheimer's disease, Multiple Sclerosis, Epilepsy, Depression and Schizophrenia.
 
ABOUT NEUROGENERATION:
 
NeuroGeneration is a life science company designing new cellular therapies and biological modulators for the prevention and treatment of neurodegenerative disorders. The company has completed a Phase I clinical trial for Parkinson's disease using adult-derived autologous neural stem cells. It intends to complete a Phase II study for the treatment of Parkinson's disease as soon as it receives final approval from the FDA. NeuroGeneration's Division of Biotherapeutics and Drug Discovery offers molecular products using its drug discovery platforms to target neuroprotective and endogenous repair mechanisms.

Latest stories

Related stories

Abbott to Acquire Cancer Test Maker for Around $21 Billion

In a recent move, Abbott has gone ahead and...

New Policy to Boost Medical Device Industry in China

Beijing has gone on to release a new policy...

US Lawmakers Push Access For AI-Powered Medical Devices

The US bipartisan legislation, which was introduced in the...

$622m Government Plan for South Korea Medical Device Sector

The South Korea Medical Device Sector is all set...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »